{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.78","upperLimit":"89.27","value":"72.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"CCR rate was defined as percentage of participants with complete remission/response (CR) and clinical complete remission (CRc). CR was defined as normalization of blast percentage (≤ 5%); normalization of neutrophil count (≥ 1000/microliter \\[μL\\]) and platelet count (≥ 100,000/μL); absence of leukemic blasts; 100% clearance of all skin lesions from baseline; no new lesions in participants without lesions at baseline; nodal masses regression to normal size on computed tomography (CT); and spleen and liver not palpable and nodules disappeared. CRc was defined as normalization of blast percentage (≤ 5%); normalization of neutrophil count (≥ 1000/μL) and platelet count (≥ 100,000/μL); absence of leukemic blasts; marked clearance of all skin lesions from baseline, residual hyperpigmentation or abnormality with BPDCN identified on biopsy (or no biopsy performed); nodal masses regression to normal size on CT; and spleen and liver not palpable and nodules disappeared.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received IMGN632 via IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"Frontline De Novo BPDCN Participants - Schedule A: IMGN632 0.045 mg/kg"}],"paramType":"NUMBER","populationDescription":"Modified Intent-to-treat (mITT) Population included all participants who were eligible based on the screening criteria and who received at least 1 dose of study drug. Here, 'Overall number of participants analyzed' = Frontline de novo BPDCN participants. Per protocol, this endpoint evaluated only Frontline De Novo BPDCN Participants, all of whom were in arm Schedule A: IMGN632 0.045 mg/kg.","reportingStatus":"POSTED","timeFrame":"Up to approximately 81 months","title":"Composite Complete Remission/Response (CCR) Rate As Assessed by Investigator in Frontline De Novo Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Participants","type":"PRIMARY","unitOfMeasure":"percentage of participants"}